
BERLIN, Sept 26 (Reuters) - Switzerland's Novartis NOVN.S said on Friday that a new U.S. pharmaceutical tariff "should have no impact" on its activities, pointing to a $23 billion investment in U.S. infrastructure and the construction of new sites in the country.
"We are working to ensure that all major Novartis medicines for U.S. patients are manufactured in the U.S.," the company said in a statement. "Against this backdrop, the announced 100% tariff should have no impact on Novartis."